These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 32629782)

  • 1. Contribution of Immune Cells to Glucocorticoid Receptor Expression in Breast Cancer.
    Gandhi S; Elkhanany A; Oshi M; Dai T; Opyrchal M; Mohammadpour H; Repasky EA; Takabe K
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629782
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
    Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
    Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucocorticoid receptor modulation decreases ER-positive breast cancer cell proliferation and suppresses wild-type and mutant ER chromatin association.
    Tonsing-Carter E; Hernandez KM; Kim CR; Harkless RV; Oh A; Bowie KR; West-Szymanski DC; Betancourt-Ponce MA; Green BD; Lastra RR; Fleming GF; Chandarlapaty S; Conzen SD
    Breast Cancer Res; 2019 Jul; 21(1):82. PubMed ID: 31340854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Expression of microRNA-143 is Associated with Favorable Tumor Immune Microenvironment and Better Survival in Estrogen Receptor Positive Breast Cancer.
    Tokumaru Y; Asaoka M; Oshi M; Katsuta E; Yan L; Narayanan S; Sugito N; Matsuhashi N; Futamura M; Akao Y; Yoshida K; Takabe K
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32370060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the glucocorticoid receptor is associated with poor prognosis in estrogen receptor-negative breast cancer.
    Pan D; Kocherginsky M; Conzen SD
    Cancer Res; 2011 Oct; 71(20):6360-70. PubMed ID: 21868756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid receptor-IRS-1 axis controls EMT and the metastasis of breast cancers.
    Shi W; Wang D; Yuan X; Liu Y; Guo X; Li J; Song J
    J Mol Cell Biol; 2019 Dec; 11(12):1042-1055. PubMed ID: 30726932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Glucocorticoid Receptor (GR) Activity Signature Using Selective GR Antagonism in ER-Negative Breast Cancer.
    West DC; Kocherginsky M; Tonsing-Carter EY; Dolcen DN; Hosfield DJ; Lastra RR; Sinnwell JP; Thompson KJ; Bowie KR; Harkless RV; Skor MN; Pierce CF; Styke SC; Kim CR; de Wet L; Greene GL; Boughey JC; Goetz MP; Kalari KR; Wang L; Fleming GF; Györffy B; Conzen SD
    Clin Cancer Res; 2018 Jul; 24(14):3433-3446. PubMed ID: 29636357
    [No Abstract]   [Full Text] [Related]  

  • 8. Overexpressing S100A9 ameliorates NK cell dysfunction in estrogen receptor-positive breast cancer.
    Liu Y; Li M; Fang Z; Gao S; Cheng W; Duan Y; Wang X; Feng J; Yu T; Zhang J; Wang T; Hu A; Zhang H; Rong Z; Shakila SS; Shang Y; Kong F; Liu J; Li Y; Ma F
    Cancer Immunol Immunother; 2024 May; 73(7):117. PubMed ID: 38713229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome.
    West DC; Pan D; Tonsing-Carter EY; Hernandez KM; Pierce CF; Styke SC; Bowie KR; Garcia TI; Kocherginsky M; Conzen SD
    Mol Cancer Res; 2016 Aug; 14(8):707-19. PubMed ID: 27141101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential role of glucocorticoid receptor based on its cell type specific expression on tumor cells and infiltrating lymphocytes.
    Snijesh VP; Nimbalkar VP; Patil S; Rajarajan S; Anupama CE; Mahalakshmi S; Alexander A; Soundharya R; Ramesh R; Srinath BS; Jolly MK; Prabhu JS
    Transl Oncol; 2024 Jul; 45():101957. PubMed ID: 38643748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late recurrence of breast cancer is associated with pro-cancerous immune microenvironment in the primary tumor.
    Takeshita T; Yan L; Asaoka M; Rashid O; Takabe K
    Sci Rep; 2019 Nov; 9(1):16942. PubMed ID: 31729458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous Glucocorticoid Signaling Regulates CD8
    Acharya N; Madi A; Zhang H; Klapholz M; Escobar G; Dulberg S; Christian E; Ferreira M; Dixon KO; Fell G; Tooley K; Mangani D; Xia J; Singer M; Bosenberg M; Neuberg D; Rozenblatt-Rosen O; Regev A; Kuchroo VK; Anderson AC
    Immunity; 2020 Sep; 53(3):658-671.e6. PubMed ID: 32937153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucocorticoid receptor-mediated oncogenic activity is dependent on breast cancer subtype.
    Clark AB; Conzen SD
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106518. PubMed ID: 38734115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid receptor and breast cancer.
    Vilasco M; Communal L; Mourra N; Courtin A; Forgez P; Gompel A
    Breast Cancer Res Treat; 2011 Nov; 130(1):1-10. PubMed ID: 21818591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival.
    Okano M; Oshi M; Butash AL; Asaoka M; Katsuta E; Peng X; Qi Q; Yan L; Takabe K
    Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminal breast cancer identity is determined by loss of glucocorticoid receptor activity.
    Prekovic S; Chalkiadakis T; Roest M; Roden D; Lutz C; Schuurman K; Opdam M; Hoekman L; Abbott N; Tesselaar T; Wajahat M; Dwyer AR; Mayayo-Peralta I; Gomez G; Altelaar M; Beijersbergen R; Győrffy B; Young L; Linn S; Jonkers J; Tilley W; Hickey T; Vareslija D; Swarbrick A; Zwart W
    EMBO Mol Med; 2023 Dec; 15(12):e17737. PubMed ID: 37902007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucocorticoid receptors orchestrate a convergence of host and cellular stress signals in triple negative breast cancer.
    Posani SH; Gillis NE; Lange CA
    J Steroid Biochem Mol Biol; 2024 Oct; 243():106575. PubMed ID: 38950871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 3 NR3C1 Mutations in the Pathogenesis of Pituitary ACTH Adenoma.
    Miao H; Liu Y; Lu L; Gong F; Wang L; Duan L; Yao Y; Wang R; Chen S; Mao X; Zhang D; Heaney AP; Zhu H
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34427636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid Receptor: A Multifaceted Actor in Breast Cancer.
    Noureddine LM; Trédan O; Hussein N; Badran B; Le Romancer M; Poulard C
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regulation in breast cancer cells.
    Ogara MF; Rodríguez-Seguí SA; Marini M; Nacht AS; Stortz M; Levi V; Presman DM; Vicent GP; Pecci A
    Nucleic Acids Res; 2019 Nov; 47(20):10645-10661. PubMed ID: 31598691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.